8 September 2020
Pfizer and BioNTech have secured regulatory approval from the Paul-Ehrlich-Institut in Germany to conduct a Phase II/III clinical trial of their Covid-19 vaccine candidate, BNT162b2. The trial is part of the global pivotal Phase II/III programme launched by BioNTech and Pfizer in July this year. It is designed to assess the safety and efficacy of the vaccine candidate in up to 30,000 participants aged 18 to 85 years.
The Philippines has plans to discuss a potential Covid-19 vaccine supply deal with Australian biotech company CSL and its partner University of Queensland, according to a senior health official. Government officials are set to meet CSL and the University of Queensland representatives, but a timeframe has not been disclosed. Also, the Philippines is in talks with the World Health Organization, Russia, China, as well as Pfizer and Moderna for potential supply agreements.
Destiny Pharma has partnered with SporeGen to jointly develop the latter’s SPOR-COV product as a preventive treatment against Covid-19. The partners aim to complete a pre-clinical programme and be ready to enter the first human clinical trials within 18 months. The SPOR‑COV product is made up of a Bacillus bacteria formulation that will be administered as a nasal spray.
Shanghai Fosun Pharmaceutical has entered into a strategic agreement with Sinopharm Group for the supply of a Covid-19 vaccine candidate being developed by BioNTech. The companies intend to jointly establish a cold chain system to store and distribute the vaccine.